Newly reported from ACC 2024: Modified On-Treatment Analysis Confirms Results of TRANSFORM-HF

A modified on-treatment analysis of the TRANSFORM-HF trial presented at the American College of Cardiology 2024 (ACC.24) Annual Scientific Sessions showed no meaningful changes in study outcomes between torsemide and furosemide treatment in heart failure hospitalizations after discharge.

“Even with that, we still saw the same result: that there was no difference between these 2 medications,” explained Veraprapas Kittipibul, MD, cardiology and research fellow at Duke University Medical Center, in an interview with HCPLive. “And back to your point we shouldn’t be debating about which one is better but how can we maybe find the right dose for the right patient.”

Source: MDMag

To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.